indazoles has been researched along with Adrenal Cortex Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balasubramaniam, S; Edgerly, M; Fojo, T; Nguyen, D; O'Sullivan, C; Pittaluga, S; Velarde, M; Venkatesan, AM; Wilkerson, J; Yang, SX | 1 |
| Berruti, A; Dogliotti, L; Orlandi, L; Villa, R; Zaffaroni, N | 1 |
1 trial(s) available for indazoles and Adrenal Cortex Cancer
| Article | Year |
|---|---|
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Indazoles; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |
1 other study(ies) available for indazoles and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Agents; Drug Synergism; Humans; Indazoles; Mitotane; Tumor Cells, Cultured | 1999 |